Silexion Therapeutics to present innovative pancreatic cancer treatment at Noble Capital conference

From GlobeNewswire: 2024-11-20 08:30:00

Silexion Therapeutics Corp. (NASDAQ: SLXN) will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, Florida. Ilan Hadar, CEO, will present on the innovative approach to treating pancreatic cancer on December 4, 2024, at 11:30 am. The company’s first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is dedicated to developing RNAi therapies for KRAS-driven cancers to improve patient outcomes. Interested investors can schedule one-on-one meetings with the management team during the summit.



Read more at GlobeNewswire: Silexion Therapeutics to Present at the Noble Capital